The Cancer Vaccine Collaborative
The CVC is an innovative partnership between two not-for-profit institutions, each with a long and distinguished history in the field of cancer immunology. The Cancer Research Institute (CRI) and the Ludwig Institute for Cancer Research (LICR) have committed themselves to taking responsibility for translating their laboratory discoveries into effective cancer therapies. The establishment of the CVC, a network of eminent scientists and clinicians at leading research and medical centers around the world, is a visible manifestation of this shared commitment.
The CVC employs a unique academic organizational structure that plans, sponsors, and conducts early-phase clinical trials to test the potential therapeutic benefit of research findings made by both organizations. A committee of scientists and clinicians from CRI and LICR works closely with select investigators at other leading institutions throughout the world to design the studies. CRI provides funding for the research components of the trials, including personnel, laboratory equipment, and the establishment of typing and monitoring laboratories. LICR provides funding, expertise in immunology, protocol design and development, the process development and production of clinical reagents, and the clinical trials infrastructure, including data management and regulatory compliance.
Lloyd J. Old, M.D.
Director, Ludwig Institute for Cancer Research and
Director, Cancer Vaccine Collaborative
Jill O’Donnell-Tormey, Ph.D.,
Executive Director, Cancer Research Institute